Wade Macedone is the esteemed Chief Executive Officer of Andelyn Biosciences, a pioneering company in the gene and cell therapy manufacturing industry. With a career spanning over three decades, Wade has established himself as a visionary leader in the pharmaceutical and biotechnology sectors.

Wade’s journey in the industry began with a solid foundation in chemistry, earning a Bachelor of Science degree from the University of Pittsburgh. His academic pursuits also included polymer sciences, business management, and mathematics, equipping him with a diverse skill set that would propel his professional trajectory.

Before his tenure at Andelyn Biosciences, Wade honed his expertise at Boehringer Ingelheim/Roxane Laboratory Inc., where he held various leadership roles from 1996 to 2018. His responsibilities encompassed site strategy, product development, quality, business growth, commercial manufacturing, and global product launch.

In September of 2020, Wade took on the role of Chief Operations Officer at Andelyn Biosciences, following the company’s spin-off from Nationwide Children’s GMP clinical manufacturing facility. His promotion to CEO came after a national search, recognizing his extensive experience in clinical manufacturing and business operations.

Wade’s leadership at Andelyn Biosciences is marked by a commitment to advancing innovative therapies. Under his guidance, the company has produced over 450 GMP clinical sublots, supporting more than 75 worldwide clinical trials. His strategic vision continues to drive Andelyn towards new horizons in medical science, making life-saving treatments more accessible to patients around the globe.